About ZemairaAbout ZemairaEffective TherapyHigh PurityConvenienceWell ToleratedWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Receive Zemaira at no charge for up to 2 weeks.

Convenience

Saves patients time. Gives patients freedom.
Added Convenience with Zemaira

*Based on recommended dosage as stated in the product package inserts of 60 mg/kg body weight at the infusion rate of 0.06 mL/kg/min.

†Based on 1,000mg of Zemaira® reconstituted in only 20mL Sterile Water for Injection vs. 50mL for AralastTM.

Zemaira® provides patients with half or less the infusion time.*,1,2

The shorter infusion time makes Zemaira® convenient for patients who must receive injections on a weekly basis. In addition, Zemaira® offers:

  • Less volume per infusion†1,2
  • Room temperature storage and transport
  • Easy reconstitution
 Aralast™ is a trademark of Baxter International inc.
Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. Aralast™ Alpha1-Proteinase Inhibitor (Human), Full Prescribing Information, January 2007.
  2. Data on file, CSL Behring LLC.